Literature DB >> 16390389

Is immunity in diabetic patients influencing the susceptibility to infections? Immunoglobulins, complement and phagocytic function in children and adolescents with type 1 diabetes mellitus.

Raphael Del Roio Liberatore1, Sonia F C Barbosa, Maria das Graças Alkimin, Raquel Bellinati-Pires, Marlene P C Florido, Lourdes Isaac, Michael Kirschfink, Anete Sevciovic Grumach.   

Abstract

OBJECTIVE: Previous reports suggest an increased susceptibility of diabetes patients to infections, but little information is available on possible underlying immunologic dysfunctions. The aim of this study was to evaluate humoral factors in pediatric patients with type 1 diabetes mellitus.
METHODS: There were 66 diabetic patients (39 males:27 females; 5-17 yr) classified into two groups according to levels of glycohemoglobin (limit 9%): Group C - controlled (n = 33) and Group UC - uncontrolled (n = 33). We evaluated five patients in C and six in UC who reported previous infections. Immunologic analysis included measurement of plasma concentrations of immunoglobulins (Ig), C3, and C4 levels (turbidimetry); functional hemolytic assays for complement evaluation (CPH for classical and APH for alternative pathways), quantification of C4 isotypes C4A and C4B (ELISA), phagocytosis assays, measurement of bactericidal activity against Staphylococcus aureus, as well as tests of fungicidal capacity for Candida albicans.
RESULTS: The UC Group had higher mean age, received higher insulin doses, and had higher concentrations of glycohemoglobin than the C Group. No significant differences in duration of the disease or nutritional conditions were detected between the groups. Lower IgA values in C (10/33) and lower IgG levels in UC (23/33) were detected, and there were inverse relationship with HbA1c values. Analysis of CPH, APH, C3, and C4 showed normal levels in both groups and no statistical correlation with the HbA1c. However, 9/33 children of the UC Group had decreased C3 values. C4B levels were below the normal range in 8/20 and correlated with higher HbA1c. Both phagocytic assays for S. aureus and Candida albicans were within normal limits.
CONCLUSIONS: Low IgG concentrations and to some degree reduction in C4B levels were related to impaired metabolic control. No strong link between the immunological alterations was found in diabetic patients and the occurrence of infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16390389     DOI: 10.1111/j.1399-543X.2005.00136.x

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  15 in total

1.  Incomplete penetrance of susceptibility genes for MHC-determined immunoglobulin deficiencies in monozygotic twins discordant for type 1 diabetes.

Authors:  Chester A Alper; Zaheed Husain; Charles E Larsen; Devendra P Dubey; Rosanne Stein; Caitlin Day; Alissa Baker; Huriya Beyan; Mohammed Hawa; Thomas O Ola; R David Leslie
Journal:  J Autoimmun       Date:  2006-10-06       Impact factor: 7.094

2.  Diabetes is not associated with increased mortality in emergency department patients with sepsis.

Authors:  Philipp Schuetz; Alan E Jones; Michael D Howell; Stephen Trzeciak; Long Ngo; John G Younger; William Aird; Nathan I Shapiro
Journal:  Ann Emerg Med       Date:  2011-06-16       Impact factor: 5.721

3.  Prevalence of selective immunoglobulin A deficiency in Greek children and adolescents with type 1 diabetes.

Authors:  Styliani Giza; Eleni Kotanidou; Efimia Papadopoulou-Alataki; Maria Christina Antoniou; Ioanna Maggana; Ioannis Kyrgios; Assimina Galli-Tsinopoulou
Journal:  World J Pediatr       Date:  2016-06-10       Impact factor: 2.764

4.  Effect of hyperglycaemia on inflammatory and stress responses and clinical outcome of pneumonia in non-critical-care inpatients: results from an observational cohort study.

Authors:  Philipp Schuetz; Natalie Friedli; Eva Grolimund; Alexander Kutz; Sebastian Haubitz; Mirjam Christ-Crain; Robert Thomann; Werner Zimmerli; Claus Hoess; Christoph Henzen; Beat Mueller
Journal:  Diabetologia       Date:  2013-11-24       Impact factor: 10.122

Review 5.  The impact of diabetes on the pathogenesis of sepsis.

Authors:  G C K W Koh; S J Peacock; T van der Poll; W J Wiersinga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-30       Impact factor: 3.267

6.  Reduced neutrophil apoptosis in diabetic mice during staphylococcal infection leads to prolonged Tnfα production and reduced neutrophil clearance.

Authors:  Frank Hanses; Sunny Park; Jeremy Rich; Jean C Lee
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

Review 7.  Diabetes and sepsis: preclinical findings and clinical relevance.

Authors:  Philipp Schuetz; Pedro Castro; Nathan I Shapiro
Journal:  Diabetes Care       Date:  2011-03       Impact factor: 19.112

8.  Adiponectin-induced secretion of interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1, CCL2) and interleukin-8 (IL-8, CXCL8) is impaired in monocytes from patients with type I diabetes.

Authors:  Sabine Abke; Markus Neumeier; Johanna Weigert; Gabriele Wehrwein; Elke Eggenhofer; Andreas Schäffler; Kevin Maier; Charalampos Aslanidis; Jürgen Schölmerich; Christa Buechler
Journal:  Cardiovasc Diabetol       Date:  2006-08-30       Impact factor: 9.951

9.  Lipopolysaccharide regulated protein expression is only partly impaired in monocytes from patients with type I diabetes.

Authors:  Gabriele Wehrwein; Markus Neumeier; Andreas Schäffler; Andrea Kopp; Johanna Weigert; Sabine Abke; Jürgen Schölmerich; Christa Buechler
Journal:  Cardiovasc Diabetol       Date:  2006-03-27       Impact factor: 9.951

10.  Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study.

Authors:  Ingrid Lea Scully; Lisa Kristin McNeil; Sudam Pathirana; Christine Lee Singer; Yongdong Liu; Stanley Mullen; Douglas Girgenti; Alejandra Gurtman; Michael W Pride; Kathrin Ute Jansen; Paul L Huang; Annaliesa S Anderson
Journal:  Diabetol Metab Syndr       Date:  2017-10-03       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.